Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren1,2,3, Yuze Hua1,2,3, Boyao Yu1,2,3

  • 1NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Molecular Cancer
|February 16, 2020
PubMed

Insights

This study corrects a figure error in a previous publication. The corrected figure is now available for accurate scientific reference.

Area of Science:

  • Scientific illustration
  • Publication integrity

Context:

  • A previously published article contained an error in its figures.
  • Figure 1 was inadvertently replaced with an incorrect image.

Purpose:

  • To correct an error in a published scientific article.
  • To ensure the accuracy of presented data and illustrations.

Summary:

  • The authors identified an error post-publication where Figure 1 was replaced.
  • A correction has been issued to replace the incorrect figure with the accurate one.

Impact:

  • Ensures the integrity of the scientific record.
  • Provides accurate visual data for readers and future research.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K